PI3K/Akt/mTOR信号转导通路相关蛋白在肾透明细胞癌中的表达及其临床意义  

The roles of PI3K/Akt/mTOR signal transduction pathway related proteins in renal clear cell carcinoma

作　　者：张烁[1] 纪海勇 张志明 周福安 

机构地区：[1]新疆医科大学第二附属医院病理科,乌鲁木齐830063 [2]山东省宁津县人民医院外二科,253400 [3]山东省宁津县人民医院病理科,253400

出　　处：《广东医学》2012年第19期2894-2897,共4页Guangdong Medical Journal

摘　　要：目的研究PI3K/Akt/mTOR信号转导通路相关蛋白PI3K、mTOR、PTEN在肾透明细胞癌中的表达及相关性,探讨其与肾透明细胞癌临床特征的关系。方法采用免疫组化Envision二步法检测77例肾透明细胞癌组织(透明细胞癌组)及18例正常组肾组织(正常对照组)中PI3K、mTOR、PTEN蛋白的表达。结果 PI3K、mTOR蛋白在透明细胞癌组中阳性率高于正常对照组(P<0.05),PTEN表达低于正常对照组(P<0.05)。核分级Ⅰ～Ⅱ级的肿瘤组织PI3K、mTOR蛋白阳性率显著低于Ⅲ～Ⅳ级(P<0.05),PTEN表达高于Ⅲ～Ⅳ级(P<0.05)。临床分期Ⅰ～Ⅱ级的肿瘤组织PI3K、mTOR蛋白阳性率显著低于Ⅲ～Ⅳ级(P<0.05),PTEN表达高于Ⅲ～Ⅳ级(P<0.05)。PTEN与PI3K、mTOR蛋白在透明细胞癌中的表达均呈负相关(P<0.05);PI3K与mTOR之间呈正相关(P<0.05)。结论 PI3K/Akt/mTOR信号转导通路在透明细胞癌组织中被过度激活,与肿瘤的核分级及临床分期密切相关。Objective To investigate the expression and significance of protein-PI3K,mTOR and PTEN,which were correlated with PI3K/Akt/mTOR signaling pathway,in renal clear cell carcinoma.Methods Envision Immunohistochemistry technique was applied to assess the expression of PI3K,mTOR and PTEN in 77 formalin-fixed paraffin embedded samples of renal clear cell carcinoma and 18 normal renal tissues.Results PI3K and mTOR protein expression in renal clear cell carcinoma was significantly higher than that in normal control group,whereas the PTEN expression was signifincatly lower（P0.05）.Significant down-regulation of PI3K and mTOR proteins and up-regulation of PTEN were revealed in nuclear Grade Ⅰ and Ⅱ tumor tissues,when comparing with that in nuclear Grade Ⅲ and Ⅳ tumor tissues（P0.05）;so was in clinical Stage Ⅰ and Ⅱ,when comparing with that in clinical Stage Ⅲ and Ⅳ tumor tissues（P0.05）.PTEN in renal clear cell carcinoma was signifincatly negatively correlated with PI3K and mTOR,which were significantly positively correlated with each other（P0.05）.Conclusion PI3K/Akt/mTOR signal transduction pathway is over-activated in renal clear cell carcinoma,which is closely correlated with nuclear classification and clinical stage.

关 键 词：肾透明细胞癌 PI3K MTOR PTEN 

分 类 号：R737.11[医药卫生—肿瘤]